It has been estimated that over 9 million adults in the United States have symptomatic knee osteoarthritis1. In 2007, 611,000 total knee arthroplasties were performed in the United States2; approximately 7% of these were simultaneous-bilateral procedures (both arthroplasties were performed during the same surgical session), and 15% of the operations were staged-bilateral procedures (two sequential arthroplasties performed within the twelve-month period)3. It has been predicted that by 2030 over 3.4 million total knee arthroplasty operations will be performed each year, a 456% increase2. The resulting strain on hospitals might be dramatically reduced if the number of hospitalizations and operating room sessions associated with these knee arthroplasties could be reduced by performing more simultaneous-bilateral total knee arthroplasty procedures.
Although a patient with symptomatic bilateral knee osteoarthritis can be treated by replacing both knees during a single operative session, it is unclear whether this is as safe as performing the second arthroplasty procedure only after the patient has recovered from the first procedure. The authors of several studies have attempted to compare the incidence of complications after simultaneous-bilateral total knee arthroplasty and after staged-bilateral total knee arthroplasty with those after unilateral total knee arthroplasty4-6. In a meta-analysis, simultaneous-bilateral total knee arthroplasty was reported to be associated with a two-fold greater risk of serious cardiac complications, pulmonary complications, and mortality compared with a single unilateral total knee arthroplasty7. Another study suggested that the overall incidence of complications might be lower after simultaneous-bilateral total knee arthroplasty than after staged-bilateral arthroplasty8. However, we are aware of no randomized trials comparing the safety of these surgical strategies.
The aim of the present study was to retrospectively compare the incidence of early cardiovascular complications and death as well as the one-year incidence of revision arthroplasty due to a major joint infection or mechanical malfunction in patients who underwent simultaneous-bilateral total knee arthroplasty and patients who underwent staged-bilateral total knee arthroplasty.
Study Design
The study involved a retrospective analysis of a large administrative database of hospital discharge data. The study was approved by the University of California Davis Human Subjects Committee and by the State of California Committee for the Protection of Human Subjects.
To make a fair comparison of the outcomes after simultaneous-bilateral total knee arthroplasty and after sequential staged-bilateral total knee arthroplasty, a number of sources of bias were addressed. We specifically accounted for patients who had planned to undergo staged-bilateral total knee arthroplasty but did not undergo the second arthroplasty because of death, a serious medical complication or major orthopaedic complication, or an elective decision to forego the second procedure.
The flow diagram in Figure 1 outlines the methods and steps used to assemble the cohort of patients who had planned to undergo staged-bilateral arthroplasty (the “planned-staged” cohort) that was compared with the simultaneous-bilateral arthroplasty cohort. The number of patients in the planned-staged cohort was set equal to the sum of three quantities: (1) the number of patients who successfully completed both arthroplasties, (2) the number of patients who electively declined the planned second arthroplasty (estimated to be between 10% and 20% of the total on the basis of previous studies9-11), and (3) the number of patients who died within thirty days or experienced a major complication after the first arthroplasty. The methods that were used to estimate the number of deaths and specific complications after the first stage of the staged-bilateral arthroplasty are described in detail below.
Inclusion Criteria
We used the California Patient Discharge database, which has been extensively described elsewhere12,13. This database uses ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) coding to list the diagnoses and procedures for all patients admitted to every California public hospital. Hospital records for an individual patient, as well as death records, can be linked in series with use of an encrypted social security number. This linkage allowed late complications to be identified even if the patient was treated at a different hospital.
Linked records for all patients who underwent at least one primary total knee arthroplasty (ICD-9-CM code 81.54) between January 1, 1997, and December 31, 2007, were identified. Patients who had had a prior primary total knee arthroplasty or revision total knee arthroplasty (81.55) between 1991 and 1996 were excluded, as were patients whose records indicated the presence of a prosthetic knee (V43.65), thus minimizing the likelihood of including patients who were undergoing a second primary total knee arthroplasty. Patients coded as having cancer (190-209) or a rheumatic disease (714, 710, or 696) were also excluded.
Patients identified as having undergone simultaneous-bilateral total knee arthroplasty had to have had two primary total knee arthroplasty procedure codes entered on the same day, as required by discharge coding rules. Patients identified as having undergone staged-bilateral total knee arthroplasty had to have had two primary total knee arthroplasty procedure codes entered within 365 days, with or without an intervening revision total knee arthroplasty (00.80-00.85, 81.22, or 81.55). The remaining patients were identified as having undergone a unilateral total knee arthroplasty, and these patients were separated into two groups, those who had undergone only one total knee arthroplasty during the study period and those who had undergone a second total knee arthroplasty more than 365 days after the index total knee arthroplasty.
Outcome Evaluation
Sixteen unique outcomes were specified with use of corresponding ICD-9-CM codes (see Appendix). Acute medical complications evaluated during the first thirty days of surgery included death, myocardial infarction, a composite coronary outcome (acute myocardial infarction, coronary angioplasty or stent implantation, coronary artery bypass surgery, or postoperative shock), ischemic stroke, other perioperative cardiac complications, respiratory complications, digestive complications, and urinary complications. Complications evaluated during the first sixty days of the total knee arthroplasty were deep-vein thrombosis and pulmonary embolism.
Minor orthopaedic complications were periprosthetic joint infection that occurred within thirty days requiring liner removal, arthrotomy, debridement, synovectomy, or other excision but not subsequent revision knee arthroplasty; and “other bacterial infections,” which included osteomyelitis of the lower limb, an infected seroma, pyogenic arthritis, cellulitis of the lower limb, an infection involving the prosthesis or another device that did not require surgery, an infection caused by Staphylococcus or Pseudomonas, an infected pressure ulcer, and a urinary tract infection within thirty days.
Major orthopaedic complications included (1) a periprosthetic joint infection coupled with revision knee arthroplasty, or a periprosthetic joint infection coupled with liner removal, arthrotomy, debridement, synovectomy, or other excision more than thirty days after the arthroplasty; (2) mechanical malfunction of the prosthetic joint requiring revision arthroplasty; and (3) mechanical dysfunction of the prosthetic joint requiring either lysis of joint adhesions or manipulation of the knee under anesthesia. A major orthopaedic complication had to occur within one year after the date of the simultaneous-bilateral arthroplasty or the date of the second stage of the staged-bilateral arthroplasty.
Patients with Complications After the First Stage of a Planned Staged-Bilateral Arthroplasty
To estimate the number of patients who had an adverse outcome and dropped out after the first stage of a planned staged-bilateral total knee arthroplasty, we first generated low, intermediate, and high estimates for the death rate and the rate of each major complication after the first stage. The low estimate for each complication rate was the rate that was actually observed after the first stage of a completed staged-bilateral procedure. To generate the intermediate and the high estimate, we assembled a cohort of unilateral total knee arthroplasty patients who were matched with the patients who underwent the second stage of the staged-bilateral procedure. Each patient was matched with respect to age (within five years), sex, race and ethnicity, insurance status, the occurrence of surgery or hospitalization for other reasons within the previous ninety days, the ratio of staged-bilateral to unilateral total knee arthroplasties performed at the index hospital (by decile), calendar year (±2 years), and seven specific chronic comorbidities from the Elixhauser comorbidity index14,15 (see Appendix). The high estimate was the rate derived from the matched unilateral arthroplasty cohort, and the intermediate estimate was set equal to 75% of the high estimate, based on the reasoning that the patients selected for two sequential total knee arthroplasties were likely to be healthier than the patients undergoing a unilateral arthroplasty. The number of deaths and complications after the first planned-staged operation was then obtained by multiplying the estimated complication rate by the projected size of the planned-staged cohort. The number of complications in the planned-staged cohort was the sum of the complications after each arthroplasty.
Follow-up of staged-bilateral arthroplasty patients until one year after the second stage resulted in a longer duration of follow-up for the first arthroplasty than for the second. To adjust for this bias, we used life-table methods to determine whether to assign any knee complication that occurred more than one year after the first arthroplasty but less than one year after the second to the first or the second arthroplasty; the outcomes assigned to the first arthroplasty were then excluded since they did not occur within one year of the procedure. This adjustment reduced the number of major joint infections in the planned-staged cohort by 8%, and it reduced the number of mechanical malfunctions by 17%.
Statistical Analysis
In order to perform a multivariate analysis, specific patients had to be selected to replace the patients who had planned to undergo staged-bilateral arthroplasty but never underwent the second arthroplasty. First, substitutes were selected for the patients who opted out of the planned second arthroplasty, estimated in the principal analysis to be 10% of the number of patients who successfully underwent staged arthroplasty. Next, the number of patients who dropped out because of a major complication was calculated with use of the low, intermediate, and high estimates. The number of patients who dropped out for this reason was set equal to the expected number of complications minus the observed number of complications that occurred after the first stage of the staged-bilateral procedure and before the second stage. For example, if the intermediate estimate of the rate of major mechanical failure was ten events per thousand patients, and if 20,000 patients were in the planned-staged cohort, the expected number of major mechanical failures would equal 200. If only forty cases of major mechanical failure were actually observed, an additional 160 patients with mechanical failure were selected from the unilateral arthroplasty cohort and added to the planned-staged cohort.
To select the specific unilateral arthroplasty patients to be added to the planned-staged cohort, a logistic regression model was developed that predicted the probability that a patient who had undergone a unilateral arthroplasty would undergo an arthroplasty of the contralateral knee. The parameters used in the modeling were similar to those that were used for patient matching in the complication rate estimation. The necessary number of patients was selected from the unilateral arthroplasty cohort with use of a stratified unequal-probability sampling design in which the sampling probability, or weight, for each unilateral arthroplasty patient was proportional to the patient's predicted probability of undergoing a subsequent arthroplasty. Sampling was performed in a stratified fashion by first selecting the necessary number of patients with a specific complication and then selecting the necessary number of patients without this complication.
Separate hierarchical multivariate logistic regression analyses were performed for each outcome to compare the risk in the simultaneous-bilateral cohort with that in the planned-staged cohort. The regression analyses adjusted for age, sex, race, ethnicity, insurance status, morbid obesity, surgery within the previous ninety days, hospitalization for another reason within the previous ninety days, and the number of Elixhauser comorbidities (all treated as fixed effects) as well as for the hospital (treated as a random effect).
The incidence of major joint infection and the incidence of major malfunction of the prosthetic joint during the first two postoperative years in the unilateral arthroplasty cohort and the simultaneous-bilateral arthroplasty cohort were also calculated with use of the life-table method and compared with use of the log-rank test.
Source of Funding
This study was funded by the University of California Davis Board of Advisors; no external funding was received.
Descriptive Statistics
From 1997 through 2007, 204,285 patients who met the inclusion criteria (and thus did not appear to have previously undergone total knee arthroplasty) underwent unilateral total knee arthroplasty (n = 169,125), simultaneous-bilateral total knee arthroplasty (n = 11,445), or staged-bilateral total knee arthroplasty (n = 23,715) (Table I). The mean age of the patients who underwent simultaneous-bilateral arthroplasty was similar to that of the patients who underwent staged-bilateral arthroplasty, but a higher percentage of the former group was male, white, and had private insurance. There were moderate differences in the prevalence of specific comorbidities between the staged-bilateral and the simultaneous-bilateral cohort.
Table II shows the unadjusted rate (per thousand cases) of each specific complication or combination of complications in the simultaneous-bilateral, planned-staged, and unilateral cohorts. For the planned-staged cohort, it was assumed that 10% of patients who planned to undergo staged-bilateral total knee arthroplasty elected to forego the second arthroplasty. Table II also shows the high, intermediate, and low estimates of the true complication rates in the planned-staged cohort after the first arthroplasty. The calculated intermediate estimates were similar to the complication rates that were actually observed after the second stage of the completed staged arthroplasties. The observed rate of major orthopaedic complications among the staged-bilateral patients was higher after the second arthroplasty than after the first arthroplasty because some of the complications observed after the second arthroplasty were associated with the knee that underwent the first arthroplasty. For major orthopaedic complications, the complication rate after simultaneous-bilateral arthroplasty was similar to that after unilateral arthroplasty.
Overall, the unadjusted rate of death or an adverse coronary event (myocardial infarction, coronary artery bypass surgery, coronary stent placement, or shock) within thirty days, calculated with use of the intermediate complication rate estimate, was 3.2 events per thousand patients higher in the simultaneous-bilateral cohort than in the planned-staged cohort, but the rate of developing either a major joint infection or a major mechanical malfunction was 10.5 events per thousand lower. The unadjusted one-year rate of knee infection requiring revision arthroplasty was 5.3 per thousand patients in the simultaneous-bilateral cohort compared with 10.7 per thousand in the planned-staged cohort, again using the intermediate estimate. Death or major periprosthetic knee infection requiring revision arthroplasty occurred in 9.1 patients per thousand in the simultaneous-bilateral cohort and 13.9 per thousand in the planned-staged cohort. The risk of pulmonary embolism, a digestive complication, or a urinary complication was higher in the simultaneous-bilateral cohort, but the risk of hematoma or a respiratory complication was higher in the planned-staged cohort.
Multivariate Analysis
Figure 2 shows the odds of specific complications occurring in the simultaneous-bilateral cohort compared with the planned-staged cohort, as calculated by multivariate analysis, with use of the high, intermediate, and low (observed) estimates of the complication rates for the planned-staged cohort. Although the adjusted odds of death were significantly higher in the simultaneous-bilateral cohort than in the planned-staged cohort when the low estimate was used (odds ratio [OR] = 2.6, 95% confidence interval [CI] = 1.6 to 4.0), the risk of death was substantially less elevated when the intermediate estimate (OR = 1.3, 95% CI = 0.9 to 1.9) or the high estimate was used (OR = 1.1, 95% CI = 0.8 to 1.6). In a sensitivity analysis, increasing the percentage of patients who elected to forego the second stage of the planned staged-bilateral arthroplasty from 10% to 20% had a minor effect on the relative risk of dying within thirty days in the simultaneous-bilateral cohort compared with the planned-staged cohort (OR = 1.09 [95% CI = 0.8 to 1.6] for a 10% drop-out rate compared with OR = 1.14 [95% CI = 0.8 to 1.6] for a 20% drop-out rate, using the intermediate estimate for the complication rate).
Similarly, using the intermediate complication rate estimate, the simultaneous-bilateral cohort had higher risk-adjusted odds of myocardial infarction (OR = 1.6, 95% CI = 1.2 to 2.2), higher odds of a composite adverse coronary disease outcome (OR = 1.7, 95% CI = 1.2 to 2.2), higher odds of a pulmonary embolism (OR = 1.4, 95% CI = 1.1 to 1.8), and higher odds of a perioperative cardiac complication (OR = 1.3, 95% CI = 1.1 to 1.6); however, all of these relative odds were less elevated when the high estimate was used. There was no significant difference in the incidence of stroke between these cohorts when either the intermediate or the high estimate was used (OR = 1.0, 95% CI = 0.6 to 1.6).
Without adjusting for confounding influences, patients in the simultaneous-bilateral cohort were significantly less likely to develop a major periprosthetic knee infection requiring revision within one year (5.3 per thousand) than patients in the planned-staged cohort were (10.7 per thousand), using the intermediate estimate. After risk adjustment, the odds of developing such a knee infection were 40% lower in the simultaneous-bilateral cohort than in the planned-staged cohort (OR = 0.6, 95% CI = 0.5 to 0.7).
The simultaneous-bilateral cohort had a lower unadjusted rate of major mechanical malfunction (10.4 per thousand) than the planned-staged cohort did (14.7 per thousand), using the intermediate estimate, and the corresponding adjusted odds were significantly lower (OR = 0.7, 95% CI = 0.6 to 0.9). If the low (observed) estimate was used instead, the adjusted risk of major mechanical malfunction was higher in the simultaneous-bilateral cohort than in the planned-staged cohort (OR = 1.3, 95% CI = 0.99 to 1.6). There was no significant difference between these two cohorts in the adjusted risk of minor knee infection, deep-vein thrombosis, or respiratory complications with use of any of the estimates.
Figure 3 shows an unadjusted life-table plot of the incidence of major knee infection over a two-year time period in the simultaneous-bilateral, unilateral, and planned-staged cohorts. The time in the planned-staged cohort is measured from the date of the first arthroplasty, and separate plots are shown for the high, intermediate, and low complication rates estimates. Complications that were attributed to the first arthroplasty but that occurred more than two years after this arthroplasty (and still within the two-year period after the second arthroplasty) were not included. The observed unadjusted incidence of major knee infection within two years did not differ significantly between the unilateral cohort and the simultaneous-bilateral cohort (log rank = 1.56, p = 0.89).
Figure 4 shows a similar unadjusted life-table plot of the incidence of major mechanical malfunction over a two-year time period. Interestingly, the unadjusted incidence of major mechanical malfunction within two years was significantly lower in the simultaneous-bilateral cohort than in the unilateral cohort (log rank = -33.5, p = 0.02).
The present study was designed to minimize the sources of bias inherent in a retrospective comparison of adverse outcomes after simultaneous-bilateral total knee arthroplasty compared with two sequential unilateral arthroplasties. A cohort of patients approximating those who were intended to have been treated with staged-bilateral total knee arthroplasty was assembled. After making adjustments for risk factors likely to confound a direct comparison, this cohort was compared with patients who underwent simultaneous-bilateral total knee arthroplasty.
Prior studies have indicated a significantly higher incidence of cardiovascular complications in patients who underwent simultaneous-bilateral total knee arthroplasty compared with unilateral total knee arthroplasty or with sequential staged-bilateral total knee arthroplasty6,7,16-23. However, these previous studies of staged-bilateral total knee arthroplasty did not take into account patients who died or experienced a major complication after the first arthroplasty, and they also did not take into account patients who electively declined the second staged arthroplasty. In our study, using an intermediate estimate of the total number of deaths after the first staged knee replacement, the number of deaths in the planned-staged cohort (3.2 per thousand) did not differ significantly from the number in the simultaneous-bilateral cohort (3.8 per thousand). However, after risk adjustment, the odds of myocardial infarction and pulmonary embolism were 60% and 40% higher, respectively, after simultaneous-bilateral arthroplasty.
There were distinct advantages and disadvantages associated with simultaneous-bilateral total knee arthroplasty. The clearest advantage was a significantly lower one-year incidence of major periprosthetic joint infection. The overall rate of serious joint infection requiring revision arthroplasty was 5.3 per thousand patients in the simultaneous-bilateral cohort compared with 10.7 per thousand in the planned-staged cohort (approximately a two-fold difference). Coupled with the finding that the unadjusted incidence of major joint infection after simultaneous-bilateral arthroplasty did not differ significantly from the incidence after unilateral arthroplasty, these findings strongly suggest that the risk of periprosthetic knee joint infection is not a function of the number of joints replaced. Instead, the risk reflects the number of times that a patient undergoing knee arthroplasty enters an operating room, which is likely to represent the main source of infection24-26.
Prior studies have focused on the incidence of local wound infections rather than major periprosthetic infections. For example, Ritter et al. reported that surgical complications (wound infection, dehiscence, major hemorrhage, or mechanical complications) were less common after simultaneous-bilateral total knee arthroplasty than after staged-bilateral total knee arthroplasty6. Malinzak et al. reported that patients who underwent simultaneous-bilateral arthroplasties were three times less likely than patients who underwent staged-bilateral arthroplasties to develop a deep joint infection, but this analysis included hip and knee arthroplasties and did not adjust for other risk factors27. Other studies comparing simultaneous-bilateral and staged-bilateral total knee arthroplasties have indicated conflicting results; one suggested that simultaneous arthroplasties were associated with a higher risk of periprosthetic joint infections28, whereas another indicated that they were associated with a lower risk of superficial wound infections29.
An unexpected finding was the significantly lower one-year incidence of major mechanical failure in the simultaneous-bilateral cohort than in the planned-staged cohort. Even after risk adjustment, with use of the intermediate estimate, major mechanical failure was 26% less frequent in the simultaneous-bilateral cohort. Interestingly, the one-year incidence of major mechanical failure was 10.4 per thousand after simultaneous-bilateral total knee arthroplasty compared with 10.2 per thousand after unilateral total knee arthroplasty, and the incidence within two years was significantly lower in the simultaneous-bilateral cohort than in the unilateral cohort. Potential explanations for the lower incidence of mechanical failure after simultaneous-bilateral total knee arthroplasty than after staged-bilateral arthroplasty include a lower prevalence of morbid obesity, more intensive hospital-based physical therapy, and perhaps improved intraoperative surgical technique.
The strengths of this study include the inclusion of all patients in California who underwent total knee arthroplasty for the first time during a ten-year time period, the capability of identifying all deaths with use of a master death registry, and the capability of identifying all of the major complications that were treated at any public hospital in the state. All complications were explicitly defined with use of ICD-9-CM coding30,31, and the major orthopaedic complication codes, which have high predictive value32, were coupled to major procedure codes, which are even more reliable. By using ICD-9-CM codes to define important complications, each outcome was identified in an identical fashion in both cohorts, minimizing the likelihood that miscoding biased the findings. Important outcomes, particularly the incidence of death6,33 and of major periprosthetic joint infection after unilateral total knee arthroplasty34-36, were comparable with published rates. Most importantly, we estimated the number of complications among patients for whom staged-bilateral total knee arthroplasty was the intended treatment.
The limitations of this study include the retrospective design, the reliance on administrative data, the inability to account for the effect of individual surgeons, and the absence of measures that could characterize the severity of the nonfatal complications. Also, we could not adjust for potential confounders such as the severity of the joint disease, the use of perioperative medications, and the type, timing of administration, or duration of antibacterial prophylaxis.
In conclusion, compared with staged-bilateral total knee arthroplasty, simultaneous-bilateral total knee arthroplasty was associated with a notable reduction in the incidence of periprosthetic knee infection and mechanical failure. Because infection is now recognized as the leading cause of revision knee arthroplasty37-39, the need to develop strategies to minimize the substantial patient morbidity and economic cost associated with this complication is paramount40,41. Simultaneous-bilateral total knee arthroplasty was associated with a moderately higher risk of adverse cardiovascular outcomes within thirty days compared with staged-bilateral arthroplasty, but if patients who are at higher risk for cardiovascular complications can be identified, simultaneous-bilateral knee arthroplasty may be the preferred surgical strategy for the remaining lower-risk patients.